CytoDyn Inc (OTCPK:CYDY)
$ 0.1351 -0.00065 (-0.48%) Market Cap: 143.01 Mil Enterprise Value: 172.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 32/100

Cytodyn Inc Developing New Therapies for Treatment of Human Immunodeficiency Virus Transcript

Jun 18, 2020 / NTS GMT
Release Date Price: $3.2 (+4.23%)
Mike Elliott
The StockGeek News and Podcast - Moderator

Hi. I'm Mike Elliott and you're watching The StockGeek Podcast where we help investors find potentially profitable small- and mid-cap stocks that may be undervalued, on the verge of a breakout or have other fundamental characteristics that make them an attractive long-term opportunity.

Today, as part of our CEORoadshow series were joined by Dr. Nader Pourhassan, President and CEO of CytoDyn, a biotech company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. They trade under the ticker CYDY.

Hi, Dr. Pourhassan and welcome to the show.

Nader Pourhassan
CytoDyn Inc. - President & CEO

Thank you for having me.

Questions & Answers

Mike Elliott
The StockGeek News and Podcast - Moderator

For investors new to the story, I'd like to start off by getting an overview of what CytoDyn does, what are your primary pipeline drugs right

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot